Thomas Shellenberg

Also affiliated with Behavioral Pharma (United States), Institute of Behavioral Sciences

MedicineNeurosciencePharmacology, Toxicology and Pharmaceutics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Influence of cocaine use reduction on markers of immune function”.

Influence of cocaine use reduction on markers of immune function

Journal of Neuroimmunology(2024)10.1016/j.jneuroim.2024.578470

N/A

0.312DataRank · unranked

6 citations

Thomas Shellenberg, Sean D. Regnier, David Cox, Reuben Adatorwovor, Lon R. Hays +6 more

Cocaine abstinence during the “critical period” of a contingency management trial predicts future abstinence in people with cocaine use disorder

Drug and Alcohol Dependence(2023)10.1016/j.drugalcdep.2023.111030

N/A

0.303DataRank · unranked

4 citations

Thomas Shellenberg, Mikhail N. Koffarnus, David Cox, Joshua A. Lile, Craig R. Rush +2 more

An Evaluation of the “Critical Period” in Contingency Management

Drug and Alcohol Dependence(2024)10.1016/j.drugalcdep.2023.110617

N/A

0DataRank · unranked

0 citations

Thomas Shellenberg, Mikhail N. Koffarnus, Joshua A. Lile, Craig R. Rush, William W. Stoops +1 more

A single-blind, randomized, controlled contingency management trial on physiological indices and biomarkers of cardiovascular health in people with cocaine use disorder

Drug and Alcohol Dependence(2025)10.1016/j.drugalcdep.2025.112642

N/A

0DataRank · unranked

1 citations

Thomas Shellenberg, Sean D. Regnier, David Cox, Reuben Adatorwovor, Lon R. Hays +7 more